Dr. Mita on Treatment Selection in ER+, HER2- Breast Cancer


In Partnership With:

Monica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.

Monica M. Mita, MD, co-director, Experimental Therapeutics, professor of medicine, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, discusses treatment selection for patients with estrogen receptor (ER)–positive, HER2-negative breast cancer.

Several therapeutic options have emerged in ER-positive, HER2-negative breast cancer that prolong survival and improve quality of life, Mita explains. Typically, for patients in this population who are not in visceral crisis, which would indicate an immediate need for chemotherapeutic intervention, treatment with CDK4/6 inhibitors is the standard frontline option, Mita says.

Selecting between available CDK4/6 inhibitors is largely based on physician preference, Mita explains. However, factors including patient age, comorbidities, performance status, prior toxicities, and prior treatments should be considered during treatment selection, concludes Mita.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD